SIMILAR PATTERNS OF AMINO ACIDS FOR 4V01_B_0LIB1770_2

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	6	VAL A 588 LYS A 608 TYR A 656 ARG A 723 LEU A 731 ILE A 740	None	0.77A	4v01B-1lufA: 34.3	4v01B-1lufA: 38.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 616 VAL A 624 LYS A 644 TYR A 693 LEU A 818 ILE A 827	None	0.63A	4v01B-1rjbA: 33.3	4v01B-1rjbA: 45.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 595 VAL A 603 LYS A 623 TYR A 672 ARG A 791 LEU A 799 ILE A 808	STI A 3 ( 3.8A) STI A 3 ( 4.6A) STI A 3 (-3.7A) STI A 3 ( 4.0A) None STI A 3 (-4.4A) None	0.53A	4v01B-1t46A: 26.9	4v01B-1t46A: 48.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 595 VAL A 603 LYS A 623 TYR A 672 LEU A 799 ILE A 653	STI A 3 ( 3.8A) STI A 3 ( 4.6A) STI A 3 (-3.7A) STI A 3 ( 4.0A) STI A 3 (-4.4A) None	1.05A	4v01B-1t46A: 26.9	4v01B-1t46A: 48.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 15 VAL A 23 LYS A 38 ILE A 58 TYR A 86 LEU A 137 ILE A 146	HYM A 400 (-4.2A) HYM A 400 (-4.3A) HYM A 400 (-3.2A) None HYM A 400 (-4.7A) HYM A 400 (-4.5A) None	1.30A	4v01B-1zltA: 21.4	4v01B-1zltA: 28.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 15 VAL A 23 LYS A 38 TYR A 86 ARG A 129 LEU A 137 ILE A 146	HYM A 400 (-4.2A) HYM A 400 (-4.3A) HYM A 400 (-3.2A) HYM A 400 (-4.7A) SO4 A 901 (-2.9A) HYM A 400 (-4.5A) None	0.79A	4v01B-1zltA: 21.4	4v01B-1zltA: 28.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU X 17 VAL X 25 LYS X 39 TYR X 84 LEU X 137 ILE X 146	STU X 902 (-3.8A) STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-4.6A) STU X 902 (-4.4A) None	0.50A	4v01B-2dq7X: 30.8	4v01B-2dq7X: 37.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2f9g	MITOGEN-ACTIVATED PROTEIN KINASE FUS3 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	LEU A 19 VAL A 27 LYS A 42 ILE A 72 ARG A 136 LEU A 144	ADP A 500 (-4.3A) ADP A 500 (-4.3A) ADP A 500 (-2.9A) None None ADP A 500 (-4.3A)	0.82A	4v01B-2f9gA: 14.3	4v01B-2f9gA: 24.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hw6	MAP KINASE-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 55 VAL A 63 LYS A 78 ARG A 169 LEU A 177 ILE A 189	None	0.91A	4v01B-2hw6A: 20.1	4v01B-2hw6A: 25.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2i0e	PROTEIN KINASE C-BETA II (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 348 VAL A 356 LYS A 371 TYR A 422 ARG A 465 ILE A 482	PDS A 901 (-3.9A) PDS A 901 (-4.2A) PDS A 901 ( 4.5A) PDS A 901 (-4.7A) TPO A 500 ( 2.9A) None	0.90A	4v01B-2i0eA: 13.2	4v01B-2i0eA: 26.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jc6	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE 1D (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 29 VAL A 37 LYS A 52 ILE A 76 ARG A 143 ILE A 163	QPP A1314 (-3.7A) QPP A1314 ( 4.6A) None None None None	0.94A	4v01B-2jc6A: 21.4	4v01B-2jc6A: 26.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 251 VAL A 259 LYS A 273 TYR A 318 ARG A 363 LEU A 371 ILE A 380	None None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.7A) None 1N8 A 501 ( 4.3A) None	1.00A	4v01B-2og8A: 31.6	4v01B-2og8A: 38.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 588 VAL A 596 LYS A 616 TYR A 665 ARG A 777 LEU A 785 ILE A 794	None	0.84A	4v01B-2ogvA: 32.8	4v01B-2ogvA: 47.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 VAL A 495 ILE A 541 ILE A 548 TYR A 566 LEU A 633 ILE A 642	None	0.60A	4v01B-2psqA: 35.5	4v01B-2psqA: 73.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 487 VAL A 495 LYS A 517 ILE A 541 TYR A 566 ILE A 642	None	0.87A	4v01B-2psqA: 35.5	4v01B-2psqA: 73.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 495 ILE A 541 ILE A 548 TYR A 566 ARG A 625 LEU A 633 ILE A 642	None None None None SO4 A 303 ( 2.9A) None None	0.89A	4v01B-2psqA: 35.5	4v01B-2psqA: 73.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 724 VAL A 732 LYS A 751 ARG A 842 LEU A 850 ILE A 859	GW7 A 1 ( 4.2A) GW7 A 1 ( 4.8A) GW7 A 1 (-3.9A) None GW7 A 1 (-4.2A) None	0.96A	4v01B-2r4bA: 29.5	4v01B-2r4bA: 34.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2vuw	SERINE/THREONINE-PRO TEIN KINASE HASPIN (Homo sapiens)	PF12330 (Haspin_kinase)	6	VAL A 498 LYS A 511 ILE A 557 ARG A 648 LEU A 656 ILE A 685	5ID A1800 ( 4.5A) IOD A1799 (-3.2A) 5ID A1800 ( 4.5A) None 5ID A1800 (-4.5A) None	0.80A	4v01B-2vuwA: 15.0	4v01B-2vuwA: 24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2w4o	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE IV (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 52 VAL A 60 LYS A 75 ILE A 102 LEU A 171 ILE A 183	DKI A1338 (-3.8A) DKI A1338 (-4.2A) None DKI A1338 ( 4.4A) DKI A1338 (-4.9A) None	0.90A	4v01B-2w4oA: 21.3	4v01B-2w4oA: 24.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2wtk	SERINE/THREONINE-PRO TEIN KINASE 11 (Homo sapiens)	PF00069 (Pkinase)	6	LEU C 55 VAL C 63 ILE C 111 TYR C 131 LEU C 183 ILE C 192	ANP C 2 ( 4.4A) ANP C 2 (-4.2A) None None None None	0.72A	4v01B-2wtkC: 22.7	4v01B-2wtkC: 25.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2wtk	SERINE/THREONINE-PRO TEIN KINASE 11 (Homo sapiens)	PF00069 (Pkinase)	6	LEU C 55 VAL C 63 LYS C 78 ILE C 111 LEU C 183 ILE C 192	ANP C 2 ( 4.4A) ANP C 2 (-4.2A) ANP C 2 (-3.6A) None None None	0.76A	4v01B-2wtkC: 22.7	4v01B-2wtkC: 25.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	6	VAL A 635 LYS A 653 ILE A 683 TYR A 701 ARG A 745 LEU A 753	Q9G A1898 ( 4.7A) Q9G A1898 (-4.8A) Q9G A1898 ( 4.9A) Q9G A1898 (-4.8A) None Q9G A1898 (-4.3A)	0.77A	4v01B-2xyuA: 27.1	4v01B-2xyuA: 33.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 VAL A 495 ILE A 541 ILE A 548 TYR A 566 LEU A 633 ILE A 642	M33 A1996 (-4.0A) M33 A1996 ( 4.7A) None None M33 A1996 ( 4.7A) M33 A1996 (-4.5A) None	0.56A	4v01B-3b2tA: 26.7	4v01B-3b2tA: 86.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 VAL A 495 LYS A 517 ILE A 548 TYR A 566 LEU A 633 ILE A 642	M33 A1996 (-4.0A) M33 A1996 ( 4.7A) M33 A1996 ( 4.5A) None M33 A1996 ( 4.7A) M33 A1996 (-4.5A) None	0.70A	4v01B-3b2tA: 26.7	4v01B-3b2tA: 86.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 495 ILE A 541 ILE A 548 TYR A 566 ARG A 625 LEU A 633 ILE A 642	M33 A1996 ( 4.7A) None None M33 A1996 ( 4.7A) None M33 A1996 (-4.5A) None	0.88A	4v01B-3b2tA: 26.7	4v01B-3b2tA: 86.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 495 LYS A 517 ILE A 548 TYR A 566 ARG A 625 LEU A 633 ILE A 642	M33 A1996 ( 4.7A) M33 A1996 ( 4.5A) None M33 A1996 ( 4.7A) None M33 A1996 (-4.5A) None	0.93A	4v01B-3b2tA: 26.7	4v01B-3b2tA: 86.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 484 VAL A 492 ILE A 538 ILE A 545 TYR A 563 LEU A 630 ILE A 639	C4F A 1 ( 3.9A) None None C4F A 1 ( 4.0A) None C4F A 1 (-4.6A) None	0.60A	4v01B-3c4fA: 40.9	4v01B-3c4fA: 99.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3eb0	PUTATIVE UNCHARACTERIZED PROTEIN (Cryptosporidium parvum)	PF00069 (Pkinase)	7	LEU A 15 VAL A 23 LYS A 38 ILE A 63 TYR A 119 LEU A 173 ILE A 62	DRK A 384 (-3.8A) None None DRK A 384 ( 4.5A) DRK A 384 (-4.4A) DRK A 384 (-4.4A) None	1.43A	4v01B-3eb0A: 20.8	4v01B-3eb0A: 23.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3g2f	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 217 LYS A 230 TYR A 281 ARG A 332 LEU A 340 ILE A 349	ADP A 900 (-4.3A) ADP A 900 (-2.8A) None None ADP A 900 (-4.6A) None	0.81A	4v01B-3g2fA: 19.0	4v01B-3g2fA: 28.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 833 VAL A 841 LYS A 861 ILE A 885 TYR A 911 LEU A1029 ILE A1038	8ST A2001 ( 4.7A) 8ST A2001 ( 4.6A) 8ST A2001 (-4.0A) None 8ST A2001 (-4.9A) None None	0.67A	4v01B-3hngA: 34.7	4v01B-3hngA: 47.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3i6u	SERINE/THREONINE-PRO TEIN KINASE CHK2 (Homo sapiens)	PF00069 (Pkinase) PF00498 (FHA)	6	LEU A 226 VAL A 234 ILE A 286 ARG A 346 LEU A 354 ILE A 366	None	1.06A	4v01B-3i6uA: 21.0	4v01B-3i6uA: 23.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3is5	CALCIUM-DEPENDENT PROTEIN KINASE (Toxoplasma gondii)	PF00069 (Pkinase)	6	LEU A 141 VAL A 149 LYS A 164 ILE A 194 LEU A 267 ILE A 279	ANP A 1 (-3.9A) ANP A 1 (-4.9A) GOL A 398 ( 3.1A) ANP A 1 (-4.8A) None None	0.84A	4v01B-3is5A: 18.3	4v01B-3is5A: 28.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lij	CALCIUM/CALMODULIN DEPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 4 CALMODULIN LIKE EF HANDS (Cryptosporidium parvum)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	LEU A 68 VAL A 76 LYS A 91 ARG A 183 LEU A 191 ILE A 203	ANP A 522 (-4.6A) ANP A 522 (-4.1A) ANP A 522 (-3.5A) None ANP A 522 (-4.7A) None	0.88A	4v01B-3lijA: 23.1	4v01B-3lijA: 20.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lj0	SERINE/THREONINE-PRO TEIN KINASE/ENDORIBONUCLE ASE IRE1 (Saccharomyces cerevisiae)	PF00069 (Pkinase) PF06479 (Ribonuc_2-5A)	7	LEU A 680 VAL A 689 LYS A 702 ILE A 729 ARG A 796 LEU A 804 ILE A 826	ADP A2101 ( 4.1A) ADP A2101 (-4.5A) ADP A2101 (-2.7A) None TPO A 844 ( 3.0A) ADP A2101 (-4.4A) None	0.79A	4v01B-3lj0A: 22.0	4v01B-3lj0A: 23.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lm5	SERINE/THREONINE-PRO TEIN KINASE 17B (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 39 VAL A 47 ILE A 94 TYR A 112 LEU A 165 ILE A 177	QUE A 1 ( 3.8A) QUE A 1 ( 4.6A) QUE A 1 (-4.6A) QUE A 1 (-4.9A) None None	0.70A	4v01B-3lm5A: 24.1	4v01B-3lm5A: 23.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lm5	SERINE/THREONINE-PRO TEIN KINASE 17B (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 39 VAL A 47 LYS A 62 TYR A 112 LEU A 165 ILE A 177	QUE A 1 ( 3.8A) QUE A 1 ( 4.6A) QUE A 1 (-4.1A) QUE A 1 (-4.9A) None None	0.88A	4v01B-3lm5A: 24.1	4v01B-3lm5A: 23.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mn3	CARBON CATABOLITE-DEREPRESS ING PROTEIN KINASE (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	LEU A 61 VAL A 69 ILE A 116 TYR A 134 LEU A 184 ILE A 193	None	1.03A	4v01B-3mn3A: 20.5	4v01B-3mn3A: 28.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 216 LYS A 229 TYR A 279 ARG A 329 LEU A 337 ILE A 346	LDN A 600 (-4.5A) LDN A 600 (-4.0A) LDN A 600 (-4.7A) None LDN A 600 (-4.6A) None	1.04A	4v01B-3my0A: 24.5	4v01B-3my0A: 30.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nie	MAP2 KINASE (Plasmodium falciparum)	PF00069 (Pkinase)	6	VAL A 44 LYS A 59 ILE A 80 ILE A 90 LEU A 163 ILE A 172	ANP A 430 (-4.2A) ANP A 430 (-2.5A) None ANP A 430 ( 4.5A) ANP A 430 (-4.4A) None	0.96A	4v01B-3nieA: 20.6	4v01B-3nieA: 23.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 88 VAL A 96 LYS A 111 TYR A 161 ARG A 204 LEU A 212 ILE A 221	JOZ A 361 (-4.1A) JOZ A 361 ( 4.7A) SO4 A 5 (-2.8A) None SEP A 241 ( 3.4A) None None	0.82A	4v01B-3nuuA: 23.3	4v01B-3nuuA: 26.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	LEU A 192 VAL A 200 LYS A 215 ARG A 310 LEU A 318 ILE A 327	AMP A 577 ( 4.3A) AMP A 577 (-4.3A) AMP A 577 (-2.8A) None AMP A 577 (-4.8A) None	0.83A	4v01B-3nyoA: 21.5	4v01B-3nyoA: 20.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 484 VAL A 492 LYS A 514 ILE A 538 ILE A 545 TYR A 563 LEU A 630 ILE A 639	07J A 1 ( 4.3A) 07J A 1 (-4.0A) 07J A 1 (-4.5A) None 07J A 1 (-3.8A) 07J A 1 (-4.7A) 07J A 1 ( 4.4A) None	0.58A	4v01B-3tt0A: 39.4	4v01B-3tt0A: 92.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 544 VAL A 552 TYR A 619 ARG A 678 LEU A 686 ILE A 695	0F4 A 902 ( 4.2A) None 0F4 A 902 (-4.2A) None 0F4 A 902 (-4.5A) 0F4 A 902 (-4.6A)	0.69A	4v01B-3v5qA: 32.4	4v01B-3v5qA: 38.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3w18	AURORA KINASE A (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 139 VAL A 147 LYS A 162 TYR A 212 LEU A 263 ILE A 272	N13 A 501 (-3.7A) N13 A 501 ( 4.7A) N13 A 501 (-2.9A) N13 A 501 (-4.4A) N13 A 501 (-4.5A) None	0.72A	4v01B-3w18A: 22.8	4v01B-3w18A: 28.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 840 VAL A 848 ILE A 892 ARG A1027 LEU A1035 ILE A1044	LEV A1201 ( 3.8A) LEV A1201 ( 4.9A) None None LEV A1201 (-4.8A) None	0.75A	4v01B-3wzdA: 26.6	4v01B-3wzdA: 54.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4af3	AURORA KINASE B (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 83 VAL A 91 LYS A 106 TYR A 156 LEU A 207 ILE A 216	VX6 A 500 (-3.8A) VX6 A 500 ( 4.8A) VX6 A 500 (-3.3A) VX6 A 500 (-4.2A) VX6 A 500 (-4.6A) None	0.87A	4v01B-4af3A: 19.9	4v01B-4af3A: 27.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 840 VAL A 848 LYS A 868 ILE A 892 LEU A1035 ILE A1044	B49 A2000 (-3.7A) None B49 A2000 (-3.0A) None B49 A2000 (-4.5A) None	0.71A	4v01B-4agdA: 35.1	4v01B-4agdA: 49.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 560 VAL A 568 TYR A 635 ARG A 691 LEU A 699 ILE A 708	LTI A1839 ( 4.2A) None LTI A1839 (-4.7A) None LTI A1839 (-4.2A) None	0.91A	4v01B-4at3A: 30.7	4v01B-4at3A: 37.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4b99	MITOGEN-ACTIVATED PROTEIN KINASE 7 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 69 LYS A 84 ILE A 105 ILE A 115 LEU A 189 ILE A 198	R4L A1394 (-4.0A) None None R4L A1394 (-4.9A) R4L A1394 (-4.5A) None	1.10A	4v01B-4b99A: 21.9	4v01B-4b99A: 25.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	6	VAL A 222 LYS A 235 TYR A 285 ARG A 335 LEU A 343 ILE A 352	TAK A1507 (-4.7A) TAK A1507 ( 4.5A) TAK A1507 ( 4.6A) None TAK A1507 (-4.7A) None	1.01A	4v01B-4c02A: 24.8	4v01B-4c02A: 26.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c0t	LIKELY PROTEIN KINASE (Candida albicans)	PF00069 (Pkinase)	6	LEU A 246 ILE A 302 TYR A 320 ARG A 363 LEU A 371 ILE A 380	None	1.01A	4v01B-4c0tA: 22.9	4v01B-4c0tA: 16.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c0t	LIKELY PROTEIN KINASE (Candida albicans)	PF00069 (Pkinase)	7	LEU A 246 VAL A 254 LYS A 269 ILE A 302 TYR A 320 LEU A 371 ILE A 380	None	0.58A	4v01B-4c0tA: 22.9	4v01B-4c0tA: 16.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4cfh	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1 (Rattus norvegicus)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	7	LEU A 22 VAL A 30 LYS A 45 ILE A 77 TYR A 95 LEU A 146 ILE A 155	STU A1550 (-4.3A) None STU A1550 (-3.6A) STU A1550 ( 4.3A) STU A1550 (-4.5A) STU A1550 (-4.3A) None	0.86A	4v01B-4cfhA: 23.2	4v01B-4cfhA: 21.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4cfh	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1 (Rattus norvegicus)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	7	VAL A 30 LYS A 45 ILE A 77 TYR A 95 ARG A 138 LEU A 146 ILE A 155	None STU A1550 (-3.6A) STU A1550 ( 4.3A) STU A1550 (-4.5A) TPO A 172 ( 2.4A) STU A1550 (-4.3A) None	0.84A	4v01B-4cfhA: 23.2	4v01B-4cfhA: 21.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 VAL A 624 LYS A 655 ILE A 685 TYR A 703 ARG A 765 LEU A 773 ILE A 782	None DI1 A1000 (-4.8A) DI1 A1000 (-3.9A) DI1 A1000 (-4.5A) DI1 A1000 (-4.0A) None DI1 A1000 (-4.5A) DI1 A1000 (-4.5A)	0.94A	4v01B-4ckrA: 31.3	4v01B-4ckrA: 37.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 663 VAL A 671 ILE A 708 TYR A 739 LEU A 789 ILE A 798	AGS A1985 (-4.2A) AGS A1985 (-4.6A) None None AGS A1985 (-4.8A) None	0.70A	4v01B-4crsA: 20.8	4v01B-4crsA: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	LEU A 663 VAL A 671 LYS A 686 TYR A 739 ARG A 781 LEU A 789 ILE A 798	AGS A1985 (-4.2A) AGS A1985 (-4.6A) AGS A1985 (-3.0A) None TPO A 816 ( 3.0A) AGS A1985 (-4.8A) None	0.82A	4v01B-4crsA: 20.8	4v01B-4crsA: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4eqm	PROTEIN KINASE (Staphylococcus aureus)	PF00069 (Pkinase)	7	LEU A 16 VAL A 24 LYS A 39 TYR A 89 ARG A 132 LEU A 140 ILE A 149	ANP A 300 (-4.7A) ANP A 300 ( 4.7A) ANP A 300 (-3.1A) ANP A 300 (-4.3A) None ANP A 300 (-4.7A) None	1.35A	4v01B-4eqmA: 22.3	4v01B-4eqmA: 24.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f0i	HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 515 VAL A 523 TYR A 590 ARG A 648 LEU A 656 ILE A 665	None	0.92A	4v01B-4f0iA: 26.4	4v01B-4f0iA: 38.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fg8	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE 1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 26 VAL A 34 LYS A 49 ILE A 73 LEU A 148 ILE A 160	ATP A 401 (-3.8A) ATP A 401 (-4.1A) ATP A 401 (-3.0A) None ATP A 401 (-4.6A) None	1.03A	4v01B-4fg8A: 22.0	4v01B-4fg8A: 30.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	6	LEU A 855 VAL A 863 LYS A 882 TYR A 931 LEU A 983 ILE A 992	IZA A2001 (-3.7A) None IZA A2001 ( 4.7A) None IZA A2001 ( 4.7A) None	0.57A	4v01B-4gl9A: 28.1	4v01B-4gl9A: 35.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 156 VAL A 164 LYS A 179 TYR A 229 ARG A 273 ILE A 290	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) GOL A 503 ( 2.8A) 0XZ A 501 ( 4.9A) TPO A 308 ( 2.9A) None	0.84A	4v01B-4gv1A: 21.2	4v01B-4gv1A: 23.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 828 VAL A 836 LYS A 855 TYR A 904 LEU A 956 ILE A 965	19S A1201 (-3.9A) 19S A1201 (-4.4A) 19S A1201 (-3.5A) 19S A1201 (-4.7A) 19S A1201 (-4.5A) None	0.58A	4v01B-4hviA: 29.9	4v01B-4hviA: 35.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	7	LEU A 132 VAL A 140 LYS A 158 ILE A 190 ARG A 251 LEU A 259 ILE A 268	None	0.96A	4v01B-4hzsA: 27.4	4v01B-4hzsA: 33.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 132 VAL A 140 LYS A 158 ILE A 190 LEU A 259 ILE A 268	1G0 A 401 ( 4.5A) 1G0 A 401 (-4.4A) 1G0 A 401 (-3.7A) 1G0 A 401 (-4.3A) 1G0 A 401 (-4.6A) None	0.50A	4v01B-4id7A: 29.3	4v01B-4id7A: 37.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 273 VAL A 281 LYS A 295 TYR A 340 ARG A 385 LEU A 393	0J9 A 601 (-4.0A) 0J9 A 601 (-4.4A) 0J9 A 601 ( 4.7A) 0J9 A 601 ( 4.7A) None 0J9 A 601 (-4.5A)	1.11A	4v01B-4k11A: 29.2	4v01B-4k11A: 26.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 478 VAL A 486 LYS A 508 ILE A 532 ILE A 539 TYR A 557 LEU A 624 ILE A 633	ACP A 801 (-3.8A) ACP A 801 (-4.2A) ACP A 801 (-2.7A) None None None ACP A 801 (-4.4A) None	0.56A	4v01B-4k33A: 26.9	4v01B-4k33A: 80.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	LEU A 273 VAL A 281 LYS A 295 TYR A 340 ARG A 385 LEU A 393	VGG A 601 (-3.2A) VGG A 601 ( 3.5A) VGG A 601 (-3.8A) VGG A 601 ( 4.0A) None VGG A 601 (-4.5A)	0.83A	4v01B-4lggA: 29.2	4v01B-4lggA: 36.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 903 VAL A 911 LYS A 930 ILE A 960 TYR A 980 LEU A1030 ILE A 959	2TT A1202 (-3.5A) 2TT A1202 (-4.5A) None None 2TT A1202 (-4.6A) 2TT A1202 (-4.4A) None	1.43A	4v01B-4oliA: 27.5	4v01B-4oliA: 22.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 903 VAL A 911 LYS A 930 ILE A 960 TYR A 980 LEU A1030 ILE A1039	2TT A1202 (-3.5A) 2TT A1202 (-4.5A) None None 2TT A1202 (-4.6A) 2TT A1202 (-4.4A) None	0.81A	4v01B-4oliA: 27.5	4v01B-4oliA: 22.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 627 VAL A 635 TYR A 703 ARG A 745 LEU A 753 ILE A 762	None None None TPO A 780 ( 2.8A) None None	1.02A	4v01B-4otdA: 21.6	4v01B-4otdA: 28.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4q9z	HUMAN PROTEIN KINASE C THETA (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 386 VAL A 394 LYS A 409 TYR A 460 LEU A 511 ILE A 520	PZW A 801 (-3.9A) PZW A 801 (-4.6A) None None PZW A 801 (-4.8A) None	0.72A	4v01B-4q9zA: 20.4	4v01B-4q9zA: 28.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4qny	MITOGEN ACTIVATED PROTEIN KINASE, PUTATIVE (Leishmania donovani)	PF00069 (Pkinase)	6	VAL A 35 LYS A 51 ILE A 83 ARG A 148 LEU A 156 ILE A 165	ANP A 402 (-4.3A) ANP A 402 (-2.8A) ANP A 402 (-4.8A) None ANP A 402 (-4.6A) None	0.87A	4v01B-4qnyA: 22.0	4v01B-4qnyA: 26.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rew	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1 (Homo sapiens)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	7	LEU A 24 VAL A 32 LYS A 47 ILE A 79 TYR A 97 LEU A 148 ILE A 157	STU A 601 (-3.7A) STU A 601 ( 4.8A) STU A 601 ( 3.7A) STU A 601 ( 4.6A) STU A 601 (-4.4A) STU A 601 (-4.2A) None	0.74A	4v01B-4rewA: 22.7	4v01B-4rewA: 18.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 616 VAL A 624 LYS A 644 TYR A 693 LEU A 818 ILE A 827	P30 A1001 (-3.8A) None P30 A1001 (-3.4A) P30 A1001 (-4.1A) P30 A1001 (-4.6A) P30 A1001 ( 4.8A)	0.37A	4v01B-4rt7A: 26.2	4v01B-4rt7A: 40.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	6	LEU A 14 VAL A 22 LYS A 37 ILE A 55 TYR A 83 LEU A 136	ACP A1264 ( 4.5A) ACP A1264 (-4.7A) None None ACP A1264 ( 4.5A) ACP A1264 ( 4.8A)	1.09A	4v01B-4ueuA: 30.8	4v01B-4ueuA: 41.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	6	LEU A 14 VAL A 22 LYS A 37 TYR A 83 ARG A 128 LEU A 136	ACP A1264 ( 4.5A) ACP A1264 (-4.7A) None ACP A1264 ( 4.5A) None ACP A1264 ( 4.8A)	0.59A	4v01B-4ueuA: 30.8	4v01B-4ueuA: 41.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4uy9	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 158 LYS A 171 ILE A 204 ARG A 267 LEU A 275 ILE A 292	None	0.92A	4v01B-4uy9A: 26.9	4v01B-4uy9A: 31.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wbo	RHODOPSIN KINASE (Bos taurus)	PF00069 (Pkinase) PF00615 (RGS)	6	LEU A 193 VAL A 201 LYS A 216 ARG A 313 LEU A 321 ILE A 330	ANW A 601 ( 4.0A) None None None ANW A 601 (-4.9A) None	0.92A	4v01B-4wboA: 22.4	4v01B-4wboA: 21.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xcu	FIBROBLAST GROWTH FACTOR RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 473 VAL A 481 LYS A 503 ILE A 527 ILE A 534 ARG A 611 LEU A 619 ILE A 628	40M A1002 ( 4.6A) 40M A1002 ( 4.5A) 40M A1002 (-4.0A) None 40M A1002 (-4.0A) None 40M A1002 (-4.5A) None	0.84A	4v01B-4xcuA: 37.8	4v01B-4xcuA: 73.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 616 VAL A 624 LYS A 644 TYR A 693 LEU A 818 ILE A 827	P30 A1001 (-4.0A) P30 A1001 ( 4.8A) P30 A1001 ( 4.0A) P30 A1001 ( 4.4A) P30 A1001 (-4.3A) P30 A1001 (-4.7A)	0.60A	4v01B-4xufA: 33.6	4v01B-4xufA: 49.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	6	LEU A 408 VAL A 416 LYS A 430 TYR A 476 ARG A 520 LEU A 528	746 A 702 (-3.8A) 746 A 702 ( 4.3A) 746 A 702 (-3.7A) 746 A 702 (-4.4A) None 746 A 702 (-4.4A)	1.06A	4v01B-4y93A: 30.6	4v01B-4y93A: 26.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4z7g	SERINE/THREONINE-PRO TEIN KINASE/ENDORIBONUCLE ASE IRE1 (Homo sapiens)	PF00069 (Pkinase) PF06479 (Ribonuc_2-5A)	6	LEU A 577 VAL A 586 ILE A 626 ARG A 687 LEU A 695 ILE A 709	None	0.82A	4v01B-4z7gA: 20.1	4v01B-4z7gA: 22.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4z7g	SERINE/THREONINE-PRO TEIN KINASE/ENDORIBONUCLE ASE IRE1 (Homo sapiens)	PF00069 (Pkinase) PF06479 (Ribonuc_2-5A)	6	LEU A 577 VAL A 586 LYS A 599 ARG A 687 LEU A 695 ILE A 709	None	0.97A	4v01B-4z7gA: 20.1	4v01B-4z7gA: 22.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 484 VAL A 492 LYS A 514 ILE A 538 ILE A 545 TYR A 563 LEU A 630 ILE A 639	38O A1769 (-3.2A) 38O A1769 (-4.5A) 38O A1769 ( 3.1A) None 38O A1769 ( 3.3A) 38O A1769 (-4.2A) 38O A1769 (-4.6A) None	0.54A	4v01B-5a46A: 41.4	4v01B-5a46A: 98.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 484 VAL A 492 LYS A 514 TYR A 563 ARG A 622 LEU A 630	38O A1769 (-3.2A) 38O A1769 (-4.5A) 38O A1769 ( 3.1A) 38O A1769 (-4.2A) None 38O A1769 (-4.6A)	0.91A	4v01B-5a46A: 41.4	4v01B-5a46A: 98.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ci7	SERINE/THREONINE-PRO TEIN KINASE ULK1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 30 LYS A 46 TYR A 94 ARG A 137 LEU A 145 ILE A 163	51W A 401 ( 4.3A) GOL A 404 ( 3.1A) 51W A 401 ( 3.4A) TPO A 180 ( 2.9A) 51W A 401 (-4.5A) None	0.83A	4v01B-5ci7A: 17.7	4v01B-5ci7A: 27.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 903 VAL A 911 LYS A 930 ILE A 960 TYR A 980 LEU A1030 ILE A1039	5U3 A1200 (-3.8A) 5U3 A1200 ( 4.4A) None 5U3 A1200 (-4.6A) 5U3 A1200 (-4.5A) 5U3 A1200 (-4.4A) None	0.50A	4v01B-5f1zA: 28.5	4v01B-5f1zA: 35.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 730 VAL A 738 LYS A 758 ILE A 788 TYR A 806 ARG A 873 ILE A 890	PP1 A2012 (-4.6A) PP1 A2012 (-4.4A) PP1 A2012 (-4.1A) None None SEP A 909 ( 3.0A) None	0.86A	4v01B-5fm2A: 34.1	4v01B-5fm2A: 51.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 730 VAL A 738 LYS A 758 ILE A 788 TYR A 806 LEU A 881 ILE A 890	PP1 A2012 (-4.6A) PP1 A2012 (-4.4A) PP1 A2012 (-4.1A) None None PP1 A2012 (-4.6A) None	0.68A	4v01B-5fm2A: 34.1	4v01B-5fm2A: 51.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 599 VAL A 607 LYS A 627 TYR A 676 ARG A 817 LEU A 825 ILE A 834	748 A1001 (-3.8A) 748 A1001 ( 4.7A) 748 A1001 (-4.0A) 748 A1001 (-4.0A) None 748 A1001 (-4.3A) 748 A1001 (-4.8A)	0.41A	4v01B-5grnA: 27.1	4v01B-5grnA: 46.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 599 VAL A 607 LYS A 627 TYR A 676 LEU A 825 ILE A 657	748 A1001 (-3.8A) 748 A1001 ( 4.7A) 748 A1001 (-4.0A) 748 A1001 (-4.0A) 748 A1001 (-4.3A) 748 A1001 ( 4.4A)	1.08A	4v01B-5grnA: 27.1	4v01B-5grnA: 46.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5idn	CYCLIN-DEPENDENT KINASE 8 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 35 LYS A 52 ILE A 79 TYR A 99 LEU A 158 ILE A 171	6A7 A 401 ( 4.5A) 6A7 A 401 ( 2.9A) 6A7 A 401 (-4.2A) 6A7 A 401 (-4.9A) 6A7 A 401 (-4.8A) None	0.70A	4v01B-5idnA: 6.1	4v01B-5idnA: 26.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5iso	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2 (Homo sapiens)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	6	LEU A 22 VAL A 30 ILE A 77 TYR A 95 LEU A 146 ILE A 155	STU A 601 (-4.1A) STU A 601 (-4.8A) STU A 601 ( 4.3A) STU A 601 (-4.3A) STU A 601 (-4.5A) None	0.73A	4v01B-5isoA: 22.9	4v01B-5isoA: 19.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5iso	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2 (Homo sapiens)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	6	LEU A 22 VAL A 30 LYS A 45 ILE A 77 TYR A 95 ILE A 155	STU A 601 (-4.1A) STU A 601 (-4.8A) STU A 601 ( 4.4A) STU A 601 ( 4.3A) STU A 601 (-4.3A) None	0.80A	4v01B-5isoA: 22.9	4v01B-5isoA: 19.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5tur	SERINE/THREONINE-PRO TEIN KINASE PIM-1 (Homo sapiens)	no annotation	6	LEU A 44 VAL A 52 LYS A 67 ILE A 104 ARG A 166 LEU A 174	None 7LK A 401 (-4.9A) None 7LK A 401 (-4.8A) None 7LK A 401 (-4.8A)	0.78A	4v01B-5turA: 21.5	4v01B-5turA: 23.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	6	LEU A 24 VAL A 32 LYS A 47 TYR A 97 LEU A 153 ILE A 162	9WS A 401 ( 4.2A) 9WS A 401 ( 4.6A) 9WS A 401 (-3.3A) None 9WS A 401 (-4.6A) None	0.66A	4v01B-5w5jA: 24.2	4v01B-5w5jA: 26.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	6	LEU A 891 VAL A 899 LYS A 919 TYR A 965 LEU A1017 ILE A1026	ANP A1201 (-4.1A) ANP A1201 (-4.4A) ANP A1201 (-3.8A) ANP A1201 (-4.4A) ANP A1201 (-4.7A) None	0.70A	4v01B-5wnoA: 28.2	4v01B-5wnoA: 12.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6f3d	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (Homo sapiens)	no annotation	6	VAL A 200 LYS A 213 TYR A 264 ARG A 310 LEU A 318 ILE A 327	CJT A 502 ( 4.8A) CJT A 502 (-3.0A) CJT A 502 (-4.5A) TPO A 345 ( 4.9A) CJT A 502 (-4.7A) None	0.95A	4v01B-6f3dA: 23.3	4v01B-6f3dA: 13.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fek	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	no annotation	6	LEU A 730 VAL A 738 ILE A 788 TYR A 806 LEU A 881 ILE A 890	ADN A1104 ( 4.0A) ADN A1104 (-4.4A) ADN A1104 ( 4.7A) ADN A1104 ( 4.1A) ADN A1104 (-4.3A) None	0.48A	4v01B-6fekA: 33.2	4v01B-6fekA: 18.64

[["4V01_B_0LIB1770_2","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",6,"VAL A 588;LYS A 608;TYR A 656;ARG A 723;LEU A 731;ILE A 740","None","0.77A","4v01B-1lufA:34.3","4v01B-1lufA:38.15"],["4V01_B_0LIB1770_2","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 616;VAL A 624;LYS A 644;TYR A 693;LEU A 818;ILE A 827","None","0.63A","4v01B-1rjbA:33.3","4v01B-1rjbA:45.95"],["4V01_B_0LIB1770_2","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",7,"LEU A 595;VAL A 603;LYS A 623;TYR A 672;ARG A 791;LEU A 799;ILE A 808","STI A   3 ( 3.8A);STI A   3 ( 4.6A);STI A   3 (-3.7A);STI A   3 ( 4.0A);None;STI A   3 (-4.4A);None","0.53A","4v01B-1t46A:26.9","4v01B-1t46A:48.89"],["4V01_B_0LIB1770_2","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",6,"LEU A 595;VAL A 603;LYS A 623;TYR A 672;LEU A 799;ILE A 653","STI A   3 ( 3.8A);STI A   3 ( 4.6A);STI A   3 (-3.7A);STI A   3 ( 4.0A);STI A   3 (-4.4A);None","1.05A","4v01B-1t46A:26.9","4v01B-1t46A:48.89"],["4V01_B_0LIB1770_2","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",7,"LEU A  15;VAL A  23;LYS A  38;ILE A  58;TYR A  86;LEU A 137;ILE A 146","HYM A 400 (-4.2A);HYM A 400 (-4.3A);HYM A 400 (-3.2A);None;HYM A 400 (-4.7A);HYM A 400 (-4.5A);None","1.30A","4v01B-1zltA:21.4","4v01B-1zltA:28.40"],["4V01_B_0LIB1770_2","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",7,"LEU A  15;VAL A  23;LYS A  38;TYR A  86;ARG A 129;LEU A 137;ILE A 146","HYM A 400 (-4.2A);HYM A 400 (-4.3A);HYM A 400 (-3.2A);HYM A 400 (-4.7A);SO4 A 901 (-2.9A);HYM A 400 (-4.5A);None","0.79A","4v01B-1zltA:21.4","4v01B-1zltA:28.40"],["4V01_B_0LIB1770_2","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",6,"LEU X  17;VAL X  25;LYS X  39;TYR X  84;LEU X 137;ILE X 146","STU X 902 (-3.8A);STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-4.6A);STU X 902 (-4.4A);None","0.50A","4v01B-2dq7X:30.8","4v01B-2dq7X:37.06"],["4V01_B_0LIB1770_2","2f9g","Saccharomyces cerevisiae","MITOGEN-ACTIVATED PROTEIN KINASE FUS3","PF00069(Pkinase)",6,"LEU A  19;VAL A  27;LYS A  42;ILE A  72;ARG A 136;LEU A 144","ADP A 500 (-4.3A);ADP A 500 (-4.3A);ADP A 500 (-2.9A);None;None;ADP A 500 (-4.3A)","0.82A","4v01B-2f9gA:14.3","4v01B-2f9gA:24.41"],["4V01_B_0LIB1770_2","2hw6","Homo sapiens","MAP KINASE-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 1","PF00069(Pkinase)",6,"LEU A  55;VAL A  63;LYS A  78;ARG A 169;LEU A 177;ILE A 189","None","0.91A","4v01B-2hw6A:20.1","4v01B-2hw6A:25.66"],["4V01_B_0LIB1770_2","2i0e","Homo sapiens","PROTEIN KINASE C-BETA II","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 348;VAL A 356;LYS A 371;TYR A 422;ARG A 465;ILE A 482","PDS A 901 (-3.9A);PDS A 901 (-4.2A);PDS A 901 ( 4.5A);PDS A 901 (-4.7A);TPO A 500 ( 2.9A);None","0.90A","4v01B-2i0eA:13.2","4v01B-2i0eA:26.51"],["4V01_B_0LIB1770_2","2jc6","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 1D","PF00069(Pkinase)",6,"LEU A  29;VAL A  37;LYS A  52;ILE A  76;ARG A 143;ILE A 163","QPP A1314 (-3.7A);QPP A1314 ( 4.6A);None;None;None;None","0.94A","4v01B-2jc6A:21.4","4v01B-2jc6A:26.58"],["4V01_B_0LIB1770_2","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",7,"LEU A 251;VAL A 259;LYS A 273;TYR A 318;ARG A 363;LEU A 371;ILE A 380","None;None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.7A);None;1N8 A 501 ( 4.3A);None","1.00A","4v01B-2og8A:31.6","4v01B-2og8A:38.19"],["4V01_B_0LIB1770_2","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",7,"LEU A 588;VAL A 596;LYS A 616;TYR A 665;ARG A 777;LEU A 785;ILE A 794","None","0.84A","4v01B-2ogvA:32.8","4v01B-2ogvA:47.87"],["4V01_B_0LIB1770_2","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;VAL A 495;ILE A 541;ILE A 548;TYR A 566;LEU A 633;ILE A 642","None","0.60A","4v01B-2psqA:35.5","4v01B-2psqA:73.17"],["4V01_B_0LIB1770_2","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"LEU A 487;VAL A 495;LYS A 517;ILE A 541;TYR A 566;ILE A 642","None","0.87A","4v01B-2psqA:35.5","4v01B-2psqA:73.17"],["4V01_B_0LIB1770_2","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 495;ILE A 541;ILE A 548;TYR A 566;ARG A 625;LEU A 633;ILE A 642","None;None;None;None;SO4 A 303 ( 2.9A);None;None","0.89A","4v01B-2psqA:35.5","4v01B-2psqA:73.17"],["4V01_B_0LIB1770_2","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"LEU A 724;VAL A 732;LYS A 751;ARG A 842;LEU A 850;ILE A 859","GW7 A   1 ( 4.2A);GW7 A   1 ( 4.8A);GW7 A   1 (-3.9A);None;GW7 A   1 (-4.2A);None","0.96A","4v01B-2r4bA:29.5","4v01B-2r4bA:34.50"],["4V01_B_0LIB1770_2","2vuw","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE HASPIN","PF12330(Haspin_kinase)",6,"VAL A 498;LYS A 511;ILE A 557;ARG A 648;LEU A 656;ILE A 685","5ID A1800 ( 4.5A);IOD A1799 (-3.2A);5ID A1800 ( 4.5A);None;5ID A1800 (-4.5A);None","0.80A","4v01B-2vuwA:15.0","4v01B-2vuwA:24.24"],["4V01_B_0LIB1770_2","2w4o","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE IV","PF00069(Pkinase)",6,"LEU A  52;VAL A  60;LYS A  75;ILE A 102;LEU A 171;ILE A 183","DKI A1338 (-3.8A);DKI A1338 (-4.2A);None;DKI A1338 ( 4.4A);DKI A1338 (-4.9A);None","0.90A","4v01B-2w4oA:21.3","4v01B-2w4oA:24.35"],["4V01_B_0LIB1770_2","2wtk","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 11","PF00069(Pkinase)",6,"LEU C  55;VAL C  63;ILE C 111;TYR C 131;LEU C 183;ILE C 192","ANP C   2 ( 4.4A);ANP C   2 (-4.2A);None;None;None;None","0.72A","4v01B-2wtkC:22.7","4v01B-2wtkC:25.07"],["4V01_B_0LIB1770_2","2wtk","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 11","PF00069(Pkinase)",6,"LEU C  55;VAL C  63;LYS C  78;ILE C 111;LEU C 183;ILE C 192","ANP C   2 ( 4.4A);ANP C   2 (-4.2A);ANP C   2 (-3.6A);None;None;None","0.76A","4v01B-2wtkC:22.7","4v01B-2wtkC:25.07"],["4V01_B_0LIB1770_2","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",6,"VAL A 635;LYS A 653;ILE A 683;TYR A 701;ARG A 745;LEU A 753","Q9G A1898 ( 4.7A);Q9G A1898 (-4.8A);Q9G A1898 ( 4.9A);Q9G A1898 (-4.8A);None;Q9G A1898 (-4.3A)","0.77A","4v01B-2xyuA:27.1","4v01B-2xyuA:33.44"],["4V01_B_0LIB1770_2","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;VAL A 495;ILE A 541;ILE A 548;TYR A 566;LEU A 633;ILE A 642","M33 A1996 (-4.0A);M33 A1996 ( 4.7A);None;None;M33 A1996 ( 4.7A);M33 A1996 (-4.5A);None","0.56A","4v01B-3b2tA:26.7","4v01B-3b2tA:86.50"],["4V01_B_0LIB1770_2","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;VAL A 495;LYS A 517;ILE A 548;TYR A 566;LEU A 633;ILE A 642","M33 A1996 (-4.0A);M33 A1996 ( 4.7A);M33 A1996 ( 4.5A);None;M33 A1996 ( 4.7A);M33 A1996 (-4.5A);None","0.70A","4v01B-3b2tA:26.7","4v01B-3b2tA:86.50"],["4V01_B_0LIB1770_2","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 495;ILE A 541;ILE A 548;TYR A 566;ARG A 625;LEU A 633;ILE A 642","M33 A1996 ( 4.7A);None;None;M33 A1996 ( 4.7A);None;M33 A1996 (-4.5A);None","0.88A","4v01B-3b2tA:26.7","4v01B-3b2tA:86.50"],["4V01_B_0LIB1770_2","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 495;LYS A 517;ILE A 548;TYR A 566;ARG A 625;LEU A 633;ILE A 642","M33 A1996 ( 4.7A);M33 A1996 ( 4.5A);None;M33 A1996 ( 4.7A);None;M33 A1996 (-4.5A);None","0.93A","4v01B-3b2tA:26.7","4v01B-3b2tA:86.50"],["4V01_B_0LIB1770_2","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"LEU A 484;VAL A 492;ILE A 538;ILE A 545;TYR A 563;LEU A 630;ILE A 639","C4F A   1 ( 3.9A);None;None;C4F A   1 ( 4.0A);None;C4F A   1 (-4.6A);None","0.60A","4v01B-3c4fA:40.9","4v01B-3c4fA:99.67"],["4V01_B_0LIB1770_2","3eb0","Cryptosporidium parvum","PUTATIVE UNCHARACTERIZED PROTEIN","PF00069(Pkinase)",7,"LEU A  15;VAL A  23;LYS A  38;ILE A  63;TYR A 119;LEU A 173;ILE A  62","DRK A 384 (-3.8A);None;None;DRK A 384 ( 4.5A);DRK A 384 (-4.4A);DRK A 384 (-4.4A);None","1.43A","4v01B-3eb0A:20.8","4v01B-3eb0A:23.63"],["4V01_B_0LIB1770_2","3g2f","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-2","PF00069(Pkinase)",6,"VAL A 217;LYS A 230;TYR A 281;ARG A 332;LEU A 340;ILE A 349","ADP A 900 (-4.3A);ADP A 900 (-2.8A);None;None;ADP A 900 (-4.6A);None","0.81A","4v01B-3g2fA:19.0","4v01B-3g2fA:28.27"],["4V01_B_0LIB1770_2","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"LEU A 833;VAL A 841;LYS A 861;ILE A 885;TYR A 911;LEU A1029;ILE A1038","8ST A2001 ( 4.7A);8ST A2001 ( 4.6A);8ST A2001 (-4.0A);None;8ST A2001 (-4.9A);None;None","0.67A","4v01B-3hngA:34.7","4v01B-3hngA:47.53"],["4V01_B_0LIB1770_2","3i6u","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK2","PF00069(Pkinase);PF00498(FHA)",6,"LEU A 226;VAL A 234;ILE A 286;ARG A 346;LEU A 354;ILE A 366","None","1.06A","4v01B-3i6uA:21.0","4v01B-3i6uA:23.87"],["4V01_B_0LIB1770_2","3is5","Toxoplasma gondii","CALCIUM-DEPENDENT PROTEIN KINASE","PF00069(Pkinase)",6,"LEU A 141;VAL A 149;LYS A 164;ILE A 194;LEU A 267;ILE A 279","ANP A   1 (-3.9A);ANP A   1 (-4.9A);GOL A 398 ( 3.1A);ANP A   1 (-4.8A);None;None","0.84A","4v01B-3is5A:18.3","4v01B-3is5A:28.19"],["4V01_B_0LIB1770_2","3lij","Cryptosporidium parvum","CALCIUM\/CALMODULIN DEPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 4 CALMODULIN LIKE EF HANDS","PF00069(Pkinase);PF13499(EF-hand_7)",6,"LEU A  68;VAL A  76;LYS A  91;ARG A 183;LEU A 191;ILE A 203","ANP A 522 (-4.6A);ANP A 522 (-4.1A);ANP A 522 (-3.5A);None;ANP A 522 (-4.7A);None","0.88A","4v01B-3lijA:23.1","4v01B-3lijA:20.95"],["4V01_B_0LIB1770_2","3lj0","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE\/ENDORIBONUCLEASE IRE1","PF00069(Pkinase);PF06479(Ribonuc_2-5A)",7,"LEU A 680;VAL A 689;LYS A 702;ILE A 729;ARG A 796;LEU A 804;ILE A 826","ADP A2101 ( 4.1A);ADP A2101 (-4.5A);ADP A2101 (-2.7A);None;TPO A 844 ( 3.0A);ADP A2101 (-4.4A);None","0.79A","4v01B-3lj0A:22.0","4v01B-3lj0A:23.86"],["4V01_B_0LIB1770_2","3lm5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 17B","PF00069(Pkinase)",6,"LEU A  39;VAL A  47;ILE A  94;TYR A 112;LEU A 165;ILE A 177","QUE A   1 ( 3.8A);QUE A   1 ( 4.6A);QUE A   1 (-4.6A);QUE A   1 (-4.9A);None;None","0.70A","4v01B-3lm5A:24.1","4v01B-3lm5A:23.73"],["4V01_B_0LIB1770_2","3lm5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 17B","PF00069(Pkinase)",6,"LEU A  39;VAL A  47;LYS A  62;TYR A 112;LEU A 165;ILE A 177","QUE A   1 ( 3.8A);QUE A   1 ( 4.6A);QUE A   1 (-4.1A);QUE A   1 (-4.9A);None;None","0.88A","4v01B-3lm5A:24.1","4v01B-3lm5A:23.73"],["4V01_B_0LIB1770_2","3mn3","Saccharomyces cerevisiae","CARBON CATABOLITE-DEREPRESSING PROTEIN KINASE","PF00069(Pkinase)",6,"LEU A  61;VAL A  69;ILE A 116;TYR A 134;LEU A 184;ILE A 193","None","1.03A","4v01B-3mn3A:20.5","4v01B-3mn3A:28.83"],["4V01_B_0LIB1770_2","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",6,"VAL A 216;LYS A 229;TYR A 279;ARG A 329;LEU A 337;ILE A 346","LDN A 600 (-4.5A);LDN A 600 (-4.0A);LDN A 600 (-4.7A);None;LDN A 600 (-4.6A);None","1.04A","4v01B-3my0A:24.5","4v01B-3my0A:30.35"],["4V01_B_0LIB1770_2","3nie","Plasmodium falciparum","MAP2 KINASE","PF00069(Pkinase)",6,"VAL A  44;LYS A  59;ILE A  80;ILE A  90;LEU A 163;ILE A 172","ANP A 430 (-4.2A);ANP A 430 (-2.5A);None;ANP A 430 ( 4.5A);ANP A 430 (-4.4A);None","0.96A","4v01B-3nieA:20.6","4v01B-3nieA:23.78"],["4V01_B_0LIB1770_2","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",7,"LEU A  88;VAL A  96;LYS A 111;TYR A 161;ARG A 204;LEU A 212;ILE A 221","JOZ A 361 (-4.1A);JOZ A 361 ( 4.7A);SO4 A   5 (-2.8A);None;SEP A 241 ( 3.4A);None;None","0.82A","4v01B-3nuuA:23.3","4v01B-3nuuA:26.45"],["4V01_B_0LIB1770_2","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",6,"LEU A 192;VAL A 200;LYS A 215;ARG A 310;LEU A 318;ILE A 327","AMP A 577 ( 4.3A);AMP A 577 (-4.3A);AMP A 577 (-2.8A);None;AMP A 577 (-4.8A);None","0.83A","4v01B-3nyoA:21.5","4v01B-3nyoA:20.88"],["4V01_B_0LIB1770_2","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 484;VAL A 492;LYS A 514;ILE A 538;ILE A 545;TYR A 563;LEU A 630;ILE A 639","07J A   1 ( 4.3A);07J A   1 (-4.0A);07J A   1 (-4.5A);None;07J A   1 (-3.8A);07J A   1 (-4.7A);07J A   1 ( 4.4A);None","0.58A","4v01B-3tt0A:39.4","4v01B-3tt0A:92.24"],["4V01_B_0LIB1770_2","3v5q","Homo sapiens","NT-3 GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 544;VAL A 552;TYR A 619;ARG A 678;LEU A 686;ILE A 695","0F4 A 902 ( 4.2A);None;0F4 A 902 (-4.2A);None;0F4 A 902 (-4.5A);0F4 A 902 (-4.6A)","0.69A","4v01B-3v5qA:32.4","4v01B-3v5qA:38.14"],["4V01_B_0LIB1770_2","3w18","Homo sapiens","AURORA KINASE A","PF00069(Pkinase)",6,"LEU A 139;VAL A 147;LYS A 162;TYR A 212;LEU A 263;ILE A 272","N13 A 501 (-3.7A);N13 A 501 ( 4.7A);N13 A 501 (-2.9A);N13 A 501 (-4.4A);N13 A 501 (-4.5A);None","0.72A","4v01B-3w18A:22.8","4v01B-3w18A:28.35"],["4V01_B_0LIB1770_2","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"LEU A 840;VAL A 848;ILE A 892;ARG A1027;LEU A1035;ILE A1044","LEV A1201 ( 3.8A);LEV A1201 ( 4.9A);None;None;LEV A1201 (-4.8A);None","0.75A","4v01B-3wzdA:26.6","4v01B-3wzdA:54.81"],["4V01_B_0LIB1770_2","4af3","Homo sapiens","AURORA KINASE B","PF00069(Pkinase)",6,"LEU A  83;VAL A  91;LYS A 106;TYR A 156;LEU A 207;ILE A 216","VX6 A 500 (-3.8A);VX6 A 500 ( 4.8A);VX6 A 500 (-3.3A);VX6 A 500 (-4.2A);VX6 A 500 (-4.6A);None","0.87A","4v01B-4af3A:19.9","4v01B-4af3A:27.81"],["4V01_B_0LIB1770_2","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"LEU A 840;VAL A 848;LYS A 868;ILE A 892;LEU A1035;ILE A1044","B49 A2000 (-3.7A);None;B49 A2000 (-3.0A);None;B49 A2000 (-4.5A);None","0.71A","4v01B-4agdA:35.1","4v01B-4agdA:49.58"],["4V01_B_0LIB1770_2","4at3","Homo sapiens","BDNF\/NT-3 GROWTH FACTORS RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 560;VAL A 568;TYR A 635;ARG A 691;LEU A 699;ILE A 708","LTI A1839 ( 4.2A);None;LTI A1839 (-4.7A);None;LTI A1839 (-4.2A);None","0.91A","4v01B-4at3A:30.7","4v01B-4at3A:37.34"],["4V01_B_0LIB1770_2","4b99","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 7","PF00069(Pkinase)",6,"VAL A  69;LYS A  84;ILE A 105;ILE A 115;LEU A 189;ILE A 198","R4L A1394 (-4.0A);None;None;R4L A1394 (-4.9A);R4L A1394 (-4.5A);None","1.10A","4v01B-4b99A:21.9","4v01B-4b99A:25.12"],["4V01_B_0LIB1770_2","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",6,"VAL A 222;LYS A 235;TYR A 285;ARG A 335;LEU A 343;ILE A 352","TAK A1507 (-4.7A);TAK A1507 ( 4.5A);TAK A1507 ( 4.6A);None;TAK A1507 (-4.7A);None","1.01A","4v01B-4c02A:24.8","4v01B-4c02A:26.95"],["4V01_B_0LIB1770_2","4c0t","Candida albicans","LIKELY PROTEIN KINASE","PF00069(Pkinase)",6,"LEU A 246;ILE A 302;TYR A 320;ARG A 363;LEU A 371;ILE A 380","None","1.01A","4v01B-4c0tA:22.9","4v01B-4c0tA:16.80"],["4V01_B_0LIB1770_2","4c0t","Candida albicans","LIKELY PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A 246;VAL A 254;LYS A 269;ILE A 302;TYR A 320;LEU A 371;ILE A 380","None","0.58A","4v01B-4c0tA:22.9","4v01B-4c0tA:16.80"],["4V01_B_0LIB1770_2","4cfh","Rattus norvegicus","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1","PF00069(Pkinase);PF16579(AdenylateSensor)",7,"LEU A  22;VAL A  30;LYS A  45;ILE A  77;TYR A  95;LEU A 146;ILE A 155","STU A1550 (-4.3A);None;STU A1550 (-3.6A);STU A1550 ( 4.3A);STU A1550 (-4.5A);STU A1550 (-4.3A);None","0.86A","4v01B-4cfhA:23.2","4v01B-4cfhA:21.08"],["4V01_B_0LIB1770_2","4cfh","Rattus norvegicus","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1","PF00069(Pkinase);PF16579(AdenylateSensor)",7,"VAL A  30;LYS A  45;ILE A  77;TYR A  95;ARG A 138;LEU A 146;ILE A 155","None;STU A1550 (-3.6A);STU A1550 ( 4.3A);STU A1550 (-4.5A);TPO A 172 ( 2.4A);STU A1550 (-4.3A);None","0.84A","4v01B-4cfhA:23.2","4v01B-4cfhA:21.08"],["4V01_B_0LIB1770_2","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 616;VAL A 624;LYS A 655;ILE A 685;TYR A 703;ARG A 765;LEU A 773;ILE A 782","None;DI1 A1000 (-4.8A);DI1 A1000 (-3.9A);DI1 A1000 (-4.5A);DI1 A1000 (-4.0A);None;DI1 A1000 (-4.5A);DI1 A1000 (-4.5A)","0.94A","4v01B-4ckrA:31.3","4v01B-4ckrA:37.54"],["4V01_B_0LIB1770_2","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 663;VAL A 671;ILE A 708;TYR A 739;LEU A 789;ILE A 798","AGS A1985 (-4.2A);AGS A1985 (-4.6A);None;None;AGS A1985 (-4.8A);None","0.70A","4v01B-4crsA:20.8","4v01B-4crsA:28.57"],["4V01_B_0LIB1770_2","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",7,"LEU A 663;VAL A 671;LYS A 686;TYR A 739;ARG A 781;LEU A 789;ILE A 798","AGS A1985 (-4.2A);AGS A1985 (-4.6A);AGS A1985 (-3.0A);None;TPO A 816 ( 3.0A);AGS A1985 (-4.8A);None","0.82A","4v01B-4crsA:20.8","4v01B-4crsA:28.57"],["4V01_B_0LIB1770_2","4eqm","Staphylococcus aureus","PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A  16;VAL A  24;LYS A  39;TYR A  89;ARG A 132;LEU A 140;ILE A 149","ANP A 300 (-4.7A);ANP A 300 ( 4.7A);ANP A 300 (-3.1A);ANP A 300 (-4.3A);None;ANP A 300 (-4.7A);None","1.35A","4v01B-4eqmA:22.3","4v01B-4eqmA:24.62"],["4V01_B_0LIB1770_2","4f0i","Homo sapiens","HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 515;VAL A 523;TYR A 590;ARG A 648;LEU A 656;ILE A 665","None","0.92A","4v01B-4f0iA:26.4","4v01B-4f0iA:38.10"],["4V01_B_0LIB1770_2","4fg8","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 1","PF00069(Pkinase)",6,"LEU A  26;VAL A  34;LYS A  49;ILE A  73;LEU A 148;ILE A 160","ATP A 401 (-3.8A);ATP A 401 (-4.1A);ATP A 401 (-3.0A);None;ATP A 401 (-4.6A);None","1.03A","4v01B-4fg8A:22.0","4v01B-4fg8A:30.47"],["4V01_B_0LIB1770_2","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"LEU A 855;VAL A 863;LYS A 882;TYR A 931;LEU A 983;ILE A 992","IZA A2001 (-3.7A);None;IZA A2001 ( 4.7A);None;IZA A2001 ( 4.7A);None","0.57A","4v01B-4gl9A:28.1","4v01B-4gl9A:35.78"],["4V01_B_0LIB1770_2","4gv1","Homo sapiens","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 156;VAL A 164;LYS A 179;TYR A 229;ARG A 273;ILE A 290","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);GOL A 503 ( 2.8A);0XZ A 501 ( 4.9A);TPO A 308 ( 2.9A);None","0.84A","4v01B-4gv1A:21.2","4v01B-4gv1A:23.42"],["4V01_B_0LIB1770_2","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",6,"LEU A 828;VAL A 836;LYS A 855;TYR A 904;LEU A 956;ILE A 965","19S A1201 (-3.9A);19S A1201 (-4.4A);19S A1201 (-3.5A);19S A1201 (-4.7A);19S A1201 (-4.5A);None","0.58A","4v01B-4hviA:29.9","4v01B-4hviA:35.52"],["4V01_B_0LIB1770_2","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",7,"LEU A 132;VAL A 140;LYS A 158;ILE A 190;ARG A 251;LEU A 259;ILE A 268","None","0.96A","4v01B-4hzsA:27.4","4v01B-4hzsA:33.51"],["4V01_B_0LIB1770_2","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",6,"LEU A 132;VAL A 140;LYS A 158;ILE A 190;LEU A 259;ILE A 268","1G0 A 401 ( 4.5A);1G0 A 401 (-4.4A);1G0 A 401 (-3.7A);1G0 A 401 (-4.3A);1G0 A 401 (-4.6A);None","0.50A","4v01B-4id7A:29.3","4v01B-4id7A:37.62"],["4V01_B_0LIB1770_2","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 273;VAL A 281;LYS A 295;TYR A 340;ARG A 385;LEU A 393","0J9 A 601 (-4.0A);0J9 A 601 (-4.4A);0J9 A 601 ( 4.7A);0J9 A 601 ( 4.7A);None;0J9 A 601 (-4.5A)","1.11A","4v01B-4k11A:29.2","4v01B-4k11A:26.12"],["4V01_B_0LIB1770_2","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",8,"LEU A 478;VAL A 486;LYS A 508;ILE A 532;ILE A 539;TYR A 557;LEU A 624;ILE A 633","ACP A 801 (-3.8A);ACP A 801 (-4.2A);ACP A 801 (-2.7A);None;None;None;ACP A 801 (-4.4A);None","0.56A","4v01B-4k33A:26.9","4v01B-4k33A:80.12"],["4V01_B_0LIB1770_2","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",6,"LEU A 273;VAL A 281;LYS A 295;TYR A 340;ARG A 385;LEU A 393","VGG A 601 (-3.2A);VGG A 601 ( 3.5A);VGG A 601 (-3.8A);VGG A 601 ( 4.0A);None;VGG A 601 (-4.5A)","0.83A","4v01B-4lggA:29.2","4v01B-4lggA:36.95"],["4V01_B_0LIB1770_2","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",7,"LEU A 903;VAL A 911;LYS A 930;ILE A 960;TYR A 980;LEU A1030;ILE A 959","2TT A1202 (-3.5A);2TT A1202 (-4.5A);None;None;2TT A1202 (-4.6A);2TT A1202 (-4.4A);None","1.43A","4v01B-4oliA:27.5","4v01B-4oliA:22.89"],["4V01_B_0LIB1770_2","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",7,"LEU A 903;VAL A 911;LYS A 930;ILE A 960;TYR A 980;LEU A1030;ILE A1039","2TT A1202 (-3.5A);2TT A1202 (-4.5A);None;None;2TT A1202 (-4.6A);2TT A1202 (-4.4A);None","0.81A","4v01B-4oliA:27.5","4v01B-4oliA:22.89"],["4V01_B_0LIB1770_2","4otd","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N1","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 627;VAL A 635;TYR A 703;ARG A 745;LEU A 753;ILE A 762","None;None;None;TPO A 780 ( 2.8A);None;None","1.02A","4v01B-4otdA:21.6","4v01B-4otdA:28.72"],["4V01_B_0LIB1770_2","4q9z","Homo sapiens","HUMAN PROTEIN KINASE C THETA","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 386;VAL A 394;LYS A 409;TYR A 460;LEU A 511;ILE A 520","PZW A 801 (-3.9A);PZW A 801 (-4.6A);None;None;PZW A 801 (-4.8A);None","0.72A","4v01B-4q9zA:20.4","4v01B-4q9zA:28.42"],["4V01_B_0LIB1770_2","4qny","Leishmania donovani","MITOGEN ACTIVATED PROTEIN KINASE, PUTATIVE","PF00069(Pkinase)",6,"VAL A  35;LYS A  51;ILE A  83;ARG A 148;LEU A 156;ILE A 165","ANP A 402 (-4.3A);ANP A 402 (-2.8A);ANP A 402 (-4.8A);None;ANP A 402 (-4.6A);None","0.87A","4v01B-4qnyA:22.0","4v01B-4qnyA:26.12"],["4V01_B_0LIB1770_2","4rew","Homo sapiens","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1","PF00069(Pkinase);PF16579(AdenylateSensor)",7,"LEU A  24;VAL A  32;LYS A  47;ILE A  79;TYR A  97;LEU A 148;ILE A 157","STU A 601 (-3.7A);STU A 601 ( 4.8A);STU A 601 ( 3.7A);STU A 601 ( 4.6A);STU A 601 (-4.4A);STU A 601 (-4.2A);None","0.74A","4v01B-4rewA:22.7","4v01B-4rewA:18.80"],["4V01_B_0LIB1770_2","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",6,"LEU A 616;VAL A 624;LYS A 644;TYR A 693;LEU A 818;ILE A 827","P30 A1001 (-3.8A);None;P30 A1001 (-3.4A);P30 A1001 (-4.1A);P30 A1001 (-4.6A);P30 A1001 ( 4.8A)","0.37A","4v01B-4rt7A:26.2","4v01B-4rt7A:40.49"],["4V01_B_0LIB1770_2","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",6,"LEU A  14;VAL A  22;LYS A  37;ILE A  55;TYR A  83;LEU A 136","ACP A1264 ( 4.5A);ACP A1264 (-4.7A);None;None;ACP A1264 ( 4.5A);ACP A1264 ( 4.8A)","1.09A","4v01B-4ueuA:30.8","4v01B-4ueuA:41.10"],["4V01_B_0LIB1770_2","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",6,"LEU A  14;VAL A  22;LYS A  37;TYR A  83;ARG A 128;LEU A 136","ACP A1264 ( 4.5A);ACP A1264 (-4.7A);None;ACP A1264 ( 4.5A);None;ACP A1264 ( 4.8A)","0.59A","4v01B-4ueuA:30.8","4v01B-4ueuA:41.10"],["4V01_B_0LIB1770_2","4uy9","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9","PF00069(Pkinase)",6,"VAL A 158;LYS A 171;ILE A 204;ARG A 267;LEU A 275;ILE A 292","None","0.92A","4v01B-4uy9A:26.9","4v01B-4uy9A:31.54"],["4V01_B_0LIB1770_2","4wbo","Bos taurus","RHODOPSIN KINASE","PF00069(Pkinase);PF00615(RGS)",6,"LEU A 193;VAL A 201;LYS A 216;ARG A 313;LEU A 321;ILE A 330","ANW A 601 ( 4.0A);None;None;None;ANW A 601 (-4.9A);None","0.92A","4v01B-4wboA:22.4","4v01B-4wboA:21.43"],["4V01_B_0LIB1770_2","4xcu","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 4","PF07714(Pkinase_Tyr)",8,"LEU A 473;VAL A 481;LYS A 503;ILE A 527;ILE A 534;ARG A 611;LEU A 619;ILE A 628","40M A1002 ( 4.6A);40M A1002 ( 4.5A);40M A1002 (-4.0A);None;40M A1002 (-4.0A);None;40M A1002 (-4.5A);None","0.84A","4v01B-4xcuA:37.8","4v01B-4xcuA:73.40"],["4V01_B_0LIB1770_2","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",6,"LEU A 616;VAL A 624;LYS A 644;TYR A 693;LEU A 818;ILE A 827","P30 A1001 (-4.0A);P30 A1001 ( 4.8A);P30 A1001 ( 4.0A);P30 A1001 ( 4.4A);P30 A1001 (-4.3A);P30 A1001 (-4.7A)","0.60A","4v01B-4xufA:33.6","4v01B-4xufA:49.67"],["4V01_B_0LIB1770_2","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",6,"LEU A 408;VAL A 416;LYS A 430;TYR A 476;ARG A 520;LEU A 528","746 A 702 (-3.8A);746 A 702 ( 4.3A);746 A 702 (-3.7A);746 A 702 (-4.4A);None;746 A 702 (-4.4A)","1.06A","4v01B-4y93A:30.6","4v01B-4y93A:26.44"],["4V01_B_0LIB1770_2","4z7g","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE\/ENDORIBONUCLEASE IRE1","PF00069(Pkinase);PF06479(Ribonuc_2-5A)",6,"LEU A 577;VAL A 586;ILE A 626;ARG A 687;LEU A 695;ILE A 709","None","0.82A","4v01B-4z7gA:20.1","4v01B-4z7gA:22.41"],["4V01_B_0LIB1770_2","4z7g","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE\/ENDORIBONUCLEASE IRE1","PF00069(Pkinase);PF06479(Ribonuc_2-5A)",6,"LEU A 577;VAL A 586;LYS A 599;ARG A 687;LEU A 695;ILE A 709","None","0.97A","4v01B-4z7gA:20.1","4v01B-4z7gA:22.41"],["4V01_B_0LIB1770_2","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",8,"LEU A 484;VAL A 492;LYS A 514;ILE A 538;ILE A 545;TYR A 563;LEU A 630;ILE A 639","38O A1769 (-3.2A);38O A1769 (-4.5A);38O A1769 ( 3.1A);None;38O A1769 ( 3.3A);38O A1769 (-4.2A);38O A1769 (-4.6A);None","0.54A","4v01B-5a46A:41.4","4v01B-5a46A:98.08"],["4V01_B_0LIB1770_2","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",6,"LEU A 484;VAL A 492;LYS A 514;TYR A 563;ARG A 622;LEU A 630","38O A1769 (-3.2A);38O A1769 (-4.5A);38O A1769 ( 3.1A);38O A1769 (-4.2A);None;38O A1769 (-4.6A)","0.91A","4v01B-5a46A:41.4","4v01B-5a46A:98.08"],["4V01_B_0LIB1770_2","5ci7","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE ULK1","PF00069(Pkinase)",6,"VAL A  30;LYS A  46;TYR A  94;ARG A 137;LEU A 145;ILE A 163","51W A 401 ( 4.3A);GOL A 404 ( 3.1A);51W A 401 ( 3.4A);TPO A 180 ( 2.9A);51W A 401 (-4.5A);None","0.83A","4v01B-5ci7A:17.7","4v01B-5ci7A:27.55"],["4V01_B_0LIB1770_2","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",7,"LEU A 903;VAL A 911;LYS A 930;ILE A 960;TYR A 980;LEU A1030;ILE A1039","5U3 A1200 (-3.8A);5U3 A1200 ( 4.4A);None;5U3 A1200 (-4.6A);5U3 A1200 (-4.5A);5U3 A1200 (-4.4A);None","0.50A","4v01B-5f1zA:28.5","4v01B-5f1zA:35.67"],["4V01_B_0LIB1770_2","5fm2","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","PF07714(Pkinase_Tyr)",7,"LEU A 730;VAL A 738;LYS A 758;ILE A 788;TYR A 806;ARG A 873;ILE A 890","PP1 A2012 (-4.6A);PP1 A2012 (-4.4A);PP1 A2012 (-4.1A);None;None;SEP A 909 ( 3.0A);None","0.86A","4v01B-5fm2A:34.1","4v01B-5fm2A:51.53"],["4V01_B_0LIB1770_2","5fm2","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","PF07714(Pkinase_Tyr)",7,"LEU A 730;VAL A 738;LYS A 758;ILE A 788;TYR A 806;LEU A 881;ILE A 890","PP1 A2012 (-4.6A);PP1 A2012 (-4.4A);PP1 A2012 (-4.1A);None;None;PP1 A2012 (-4.6A);None","0.68A","4v01B-5fm2A:34.1","4v01B-5fm2A:51.53"],["4V01_B_0LIB1770_2","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",7,"LEU A 599;VAL A 607;LYS A 627;TYR A 676;ARG A 817;LEU A 825;ILE A 834","748 A1001 (-3.8A);748 A1001 ( 4.7A);748 A1001 (-4.0A);748 A1001 (-4.0A);None;748 A1001 (-4.3A);748 A1001 (-4.8A)","0.41A","4v01B-5grnA:27.1","4v01B-5grnA:46.09"],["4V01_B_0LIB1770_2","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",6,"LEU A 599;VAL A 607;LYS A 627;TYR A 676;LEU A 825;ILE A 657","748 A1001 (-3.8A);748 A1001 ( 4.7A);748 A1001 (-4.0A);748 A1001 (-4.0A);748 A1001 (-4.3A);748 A1001 ( 4.4A)","1.08A","4v01B-5grnA:27.1","4v01B-5grnA:46.09"],["4V01_B_0LIB1770_2","5idn","Homo sapiens","CYCLIN-DEPENDENT KINASE 8","PF00069(Pkinase)",6,"VAL A  35;LYS A  52;ILE A  79;TYR A  99;LEU A 158;ILE A 171","6A7 A 401 ( 4.5A);6A7 A 401 ( 2.9A);6A7 A 401 (-4.2A);6A7 A 401 (-4.9A);6A7 A 401 (-4.8A);None","0.70A","4v01B-5idnA:6.1","4v01B-5idnA:26.20"],["4V01_B_0LIB1770_2","5iso","Homo sapiens","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2","PF00069(Pkinase);PF16579(AdenylateSensor)",6,"LEU A  22;VAL A  30;ILE A  77;TYR A  95;LEU A 146;ILE A 155","STU A 601 (-4.1A);STU A 601 (-4.8A);STU A 601 ( 4.3A);STU A 601 (-4.3A);STU A 601 (-4.5A);None","0.73A","4v01B-5isoA:22.9","4v01B-5isoA:19.44"],["4V01_B_0LIB1770_2","5iso","Homo sapiens","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2","PF00069(Pkinase);PF16579(AdenylateSensor)",6,"LEU A  22;VAL A  30;LYS A  45;ILE A  77;TYR A  95;ILE A 155","STU A 601 (-4.1A);STU A 601 (-4.8A);STU A 601 ( 4.4A);STU A 601 ( 4.3A);STU A 601 (-4.3A);None","0.80A","4v01B-5isoA:22.9","4v01B-5isoA:19.44"],["4V01_B_0LIB1770_2","5tur","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PIM-1","no annotation",6,"LEU A  44;VAL A  52;LYS A  67;ILE A 104;ARG A 166;LEU A 174","None;7LK A 401 (-4.9A);None;7LK A 401 (-4.8A);None;7LK A 401 (-4.8A)","0.78A","4v01B-5turA:21.5","4v01B-5turA:23.15"],["4V01_B_0LIB1770_2","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",6,"LEU A  24;VAL A  32;LYS A  47;TYR A  97;LEU A 153;ILE A 162","9WS A 401 ( 4.2A);9WS A 401 ( 4.6A);9WS A 401 (-3.3A);None;9WS A 401 (-4.6A);None","0.66A","4v01B-5w5jA:24.2","4v01B-5w5jA:26.74"],["4V01_B_0LIB1770_2","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",6,"LEU A 891;VAL A 899;LYS A 919;TYR A 965;LEU A1017;ILE A1026","ANP A1201 (-4.1A);ANP A1201 (-4.4A);ANP A1201 (-3.8A);ANP A1201 (-4.4A);ANP A1201 (-4.7A);None","0.70A","4v01B-5wnoA:28.2","4v01B-5wnoA:12.75"],["4V01_B_0LIB1770_2","6f3d","Homo sapiens","INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4","no annotation",6,"VAL A 200;LYS A 213;TYR A 264;ARG A 310;LEU A 318;ILE A 327","CJT A 502 ( 4.8A);CJT A 502 (-3.0A);CJT A 502 (-4.5A);TPO A 345 ( 4.9A);CJT A 502 (-4.7A);None","0.95A","4v01B-6f3dA:23.3","4v01B-6f3dA:13.55"],["4V01_B_0LIB1770_2","6fek","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","no annotation",6,"LEU A 730;VAL A 738;ILE A 788;TYR A 806;LEU A 881;ILE A 890","ADN A1104 ( 4.0A);ADN A1104 (-4.4A);ADN A1104 ( 4.7A);ADN A1104 ( 4.1A);ADN A1104 (-4.3A);None","0.48A","4v01B-6fekA:33.2","4v01B-6fekA:18.64"]]